Genmab AS (GMAB) — Financial Flexibility Index
Genmab AS (GMAB) has a Financial Flexibility Index of 0.04x as of December 2025. Free cash flow of $313.32 Million (operating CF $300.34 Million minus capex $12.99 Million) represents 0% of total liabilities ($7.01 Billion). Check Genmab AS (GMAB) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Genmab AS Financial Flexibility Index (2002–2025)
Historical Financial Flexibility Index trend for Genmab AS across 24 annual periods. For the full cash flow conversion analysis, see Genmab AS (GMAB) cash conversion ratio.
Annual Financial Flexibility Index for Genmab AS (2002–2025)
Year-by-year free cash flow to debt coverage for Genmab AS. Explore Genmab AS debt service capacity to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.17x | $1.22 Billion | $1.19 Billion | $7.01 Billion | ▼ -80.0% |
| 2024 | 0.87x | $7.96 Billion | $7.77 Billion | $9.11 Billion | ▼ -58.6% |
| 2023 | 2.11x | $7.76 Billion | $7.38 Billion | $3.68 Billion | ▲ +41.4% |
| 2022 | 1.49x | $4.23 Billion | $3.91 Billion | $2.84 Billion | ▲ +46.1% |
| 2021 | 1.02x | $2.48 Billion | $2.23 Billion | $2.43 Billion | ▼ -69.4% |
| 2020 | 3.33x | $6.74 Billion | $6.43 Billion | $2.02 Billion | ▲ +154.2% |
| 2019 | 1.31x | $1.44 Billion | $1.33 Billion | $1.10 Billion | ▼ -60.8% |
| 2018 | 3.34x | $1.49 Billion | $1.01 Billion | $446.64 Million | ▼ -34.1% |
| 2017 | 5.07x | $1.68 Billion | $1.59 Billion | $330.75 Million | ▲ +478.5% |
| 2016 | 0.88x | $360.83 Million | $327.72 Million | $411.54 Million | ▼ -18.4% |
| 2015 | 1.07x | $446.84 Million | $311.45 Million | $415.83 Million | ▲ +330.5% |
| 2014 | 0.25x | $208.11 Million | $132.67 Million | $833.74 Million | ▲ +327.5% |
| 2013 | -0.11x | $-117.63 Million | $-128.00 Million | $1.07 Billion | ▼ -279.8% |
| 2012 | 0.06x | $79.92 Million | $70.92 Million | $1.31 Billion | ▲ +115.3% |
| 2011 | -0.40x | $-430.02 Million | $-437.23 Million | $1.08 Billion | ▼ -300.9% |
| 2010 | 0.20x | $278.28 Million | $268.17 Million | $1.40 Billion | ▲ +133.2% |
| 2009 | -0.60x | $-553.28 Million | $-570.06 Million | $924.34 Million | ▼ -39.2% |
| 2008 | -0.43x | $-460.32 Million | $-513.33 Million | $1.07 Billion | ▼ -189.2% |
| 2007 | 0.48x | $518.74 Million | $505.90 Million | $1.08 Billion | ▲ +125.2% |
| 2006 | -1.92x | $-377.68 Million | $-379.62 Million | $197.05 Million | ▼ -133.9% |
| 2005 | -0.82x | $-206.21 Million | $-208.64 Million | $251.66 Million | ▲ +79.3% |
| 2004 | -3.95x | $-359.43 Million | $-367.70 Million | $90.92 Million | ▼ -28.7% |
| 2003 | -3.07x | $-287.66 Million | $-302.36 Million | $93.67 Million | ▼ -172.3% |
| 2002 | -1.13x | $-207.50 Million | $-308.32 Million | $183.97 Million | — |